Background: Prevalence rates of smoking in people with mental illness are high and premature
Introduction
There is irrefutable evidence that people with mental illness have a reduced life expectancy compared to members of the general population [1] [2] [3] . Worryingly, this mortality gap appears to be widening 3, 4 . About 80% of these deaths are attributable to physical comorbidity and modifiable lifestyle factors rather than suicide [1] [2] [3] 5 . For instance, Lawrence et al 3 recently established in a large population based study that 77.7% of deaths were attributed to physical health comorbidity such as cardiovascular disease (29.9%) and cancer (13.5%).
One modifiable lifestyle factor that is consistently implicated as a contributory factor to this mortality gap is smoking 2, 3, 6 . Smoking is the most common substance use disorder in people with mental illness and prevalence rates are two to four times higher than members of the general population [7] [8] [9] . In the USA, people with mental illness are estimated to smoke almost one out of every two cigarettes smoked 7, 9, 10 . People with severe mental illness (SMI) are particularly at risk and are often very heavy smokers 9 and in particular it has long been known that people with schizophrenia smoke at high rates and this remains true today. For instance, Hartz et al 11 recently
established that people with schizophrenia are substantially much more likely to smoke than the general population (Odd Ratio=4.6). It is therefore unsurprising that mortality attributed to smoking is particularly high among this group. For example, Tran et al 12 found that smoking is associated with a two fold increase in cancer related deaths in those with mental illness. Others have found that mortality is higher in smokers than non-smokers with schizophrenia (Hazard Ratio=2.1) with around 12 times increased risk of cardiac death seen in patients aged 35-54 13 . Cardiac disease accounted for 43% of deaths in smokers but only 19% of deaths in non-smokers with schizophrenia 13 thus indicating the increased risk of cardiovascular disease when patients smoke. Moreover, it is estimated that quitting smoking might reduce cardiac events by 90% in this group 14 . However, smoking related mortality affects all people with mental illness, regardless of diagnosis. Callaghan et al 15 found in a large scale follow-up study covering approximately 1.7 million years that tobacco related conditions accounted for roughly 53% of total deaths in schizophrenia, 48% in bipolar
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disorder and 50% of those with depression. Overall, estimates seem to suggest that life expectancy among people with mental illness is reduced by approximately 25 years due to chronic diseases secondary to tobacco use (e.g., cardiac and pulmonary disease, 16 ) compared to 10 years among smokers without a mental illness 17 . The economic costs associated with smoking among people with mental illness are also considerable. For instance, in the United Kingdom the cost to the economy for smokers with mental illness was estimated to be £2. 34 
members of the multidisciplinary team should be the first port of call and may instigate the process of stopping smoking for the patient.
Within recent years, numerous studies have established that people with mental health problems receive suboptimal medical care as well as preventive advice and physical health screening compared to the general populations [28] [29] [30] [31] . It is currently unclear if these disparities extend to receipt of smoking cessation advice and support. Given the substantial burden of smoking on morbidity and mortality among people with mental illness, it is important that research considers if there is a disparity among smoking cessation advice given to people with mental illness compared to the general population, ideally whilst taking into account different subtypes and severity of mental ill health. Thus, the aim of the current paper was to establish if there are differences in the rates of smoking cessation advice among people with mental illness compared to those without mental illness.
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Method
We conducted a systematic review and meta-analysis in accordance with the Meta-analysis of Observational Studies in Epidemiology guidelines 32 and reported it in line with the PRISMA statement 33 following a predetermined protocol.
Eligibility criteria
Studies were eligible that: 1) included people with a diagnosis of non-organic mental illness We did not include studies reported among people with dementia/ mild cognitive impairment or learning disabilities (although to our knowledge no such papers existed). No language restrictions were placed upon potentially eligible studies. If we encountered multiple studies from the same data set at different times, we used the largest and / or most recent data. If we encountered studies that enquired about smoking cessation advice but did not report the data in the paper, we contacted the authors to acquire the variables of interest (no additional requests were necessary). .
Literature search and study selection
A C C E P T E D M A N U S C R I P T After the removal of duplicates, two independent reviewers (BS, AJM) screened the titles and abstracts of all potentially eligible articles. Both authors applied the eligibility criteria, and a list of full text articles was developed through agreement. Two reviewers (BS, AJM) then considered the full texts of these articles and the final list of included articles was reached through consensus.
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Methodological quality assessment
Two authors (AJM, BS) independently completed the methodological appraisal of included studies using the Newcastle Ottawa Scale (NOS, 35 ). The NOS provides an assessment of the quality of nonrandomised controlled trials and each article received a methodological quality score out of 9.
Articles were judged across three key areas: selection, comparability and outcomes. The NOS validity and reliability has been established and scores of 5 out of 9 were considered satisfactory quality 35 .
Data extraction
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All data extraction was conducted by two independent authors (BS, AJM) utilising a predetermined form. We extracted data regarding the study design, setting, patient information (number, demographic, type of mental illness and classification criteria), control participant information, details of the smoking cessation advice and the results.
Meta-analysis
We calculated the relative risk (RR) together with the 95% confidence intervals (CI) for each study. If we encountered odds ratios within the eligible papers, these were converted into RR using an established method 36 .
We planned subgroup analysis to compare smoking cessation advice rates in people with SMI (schizophrenia, bipolar disorders) and non-severe mental illnesses (e.g. depression,
anxiety etc) as well as specific mental disorders. Due to the anticipated heterogeneity, data was with a random effects meta-analysis 37 . Heterogeneity was calculated with the Cochran Q statistic 38 .
All data was analysed using statsdirect software. Publication bias in each of the analyses was assessed with a visual inspection of funnel plots and Egger's regression method 39 and BeggMazumdar test 40 , with a p-value <0.05 suggesting the presence of bias.
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Results
Search results, included studies and participant characteristics
The initial searches yielded 1,103 valid hits and we subsequently screened the abstracts of 460 papers. Following this, 386 papers were excluded and we considered the full texts of 74 potential articles. At this stage, the eligibility criteria were applied and 67 articles were excluded with reasons (see figure 1 for details) and 7 met the inclusion criteria. Full details of the search strategy are given in figure 1.
Figure 1 here
Details of included studies
In total, 721,658 participants were represented across the 7 cross-sectional studies including 652,847 people without a mental illness and 68,811 people with a mental illness. The mean age of people with mental illness across the studies ranged from 50.1 years to 76.1. Four of the studies were conducted in the United States 41-44 and 3 were conducted in the United Kingdom [45] [46] [47] . A range of different types of mental illness were considered within the studies but 5 provided data for individuals with SMI (mainly schizophrenia and bipolar disorder; 42, 43, [45] [46] [47] ) and 4 provided data for people with other types of mental illness 41, 43, 44, 47 . The type of smoking cessation advice varied, with 2 studies this included counselling 41, 42 and the remainder included general advice on smoking cessation and this was usually delivered by a physician. Full details of the included studies are summarised in table 1. Table 1 here
Methodological quality of the included studies
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The NOS summary scores for each article are presented in 
Meta-analysis
It was possible to pool the smoking cessation advice rates from 7 studies using 13 different samples (n=721,658). Overall, there was no significant difference in smoking cessation advice rates between those with and without a mental illness (RR=1.02, 95% CI: 0.94 -1.11, n=721,658, Q=1421, p<0.001; figure 2a ). The funnel plot was broadly symmetrical and neither the Begg (=0.205, P = 0.36) or the Egger test (=-2.27, P = 0.68) indicated any evidence of publication bias (figure 2b).
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Figure 2 a and b here
Smoking cessation advice rates among people with SMI Next, it was possible to pool smoking cessation advice rates from 5 studies incorporating 9 samples with individuals with SMI including a total of 559,122 participants (n SMI=6894, n control =552,228).
The pooled analysis demonstrated there was no significant difference in smoking cessation advice rates between people with a SMI and those without an SMI (RR=1.09, 95% CI = 0.98 -1.230; Q=242, p<0.001; figure 2 ). The pooled analysis did not demonstrate any evidence of publication bias (Begg = 0.11, p=0.61, Eggers test = 2.21, p=0.5).
Figure 3 here
We pooled data from 3 studies 43, 45, 47 to investigate if there were difference in smoking cessation advice rates in people with bipolar disorder and schizophrenia and the control populations. The random effects analysis demonstrated there were no significant differences in smoking cessation rates in people with bipolar disorder (RR=1.14 (95% CI = 0.85-1.545; Q=109,p<0.001) or schizophrenia (RR=1.09 (95% CI = 0.68-1.70; Q=109, p<0.001) compared to the control samples.
Smoking cessation rates among people with non-severe mental illness
Finally, it was possible to pool from 4 studies using 10 samples to investigate smoking cessation advices rates among people with and without a mental illness. The pooled analysis demonstrated that people with non-SMI were significantly more likely than control populations to receive smoking cessation advice (RR=1.16, 95% CI = 1.04-1.30; Q=1364, p<0.001, n mental illness=64,689, n control=515,517, figure 4 ). There was no evidence of publication bias within this analysis (Begg=0.15, P = 0.60, Egger test=5.70, =p=0.4). Finally, two studies consisted of "any mental illness" and may have included people with SMI; therefore we conducted an exploratory analysis removing these.
This established that people with any non SMI mental illness were still significantly more likely to receive smoking cessation advice (RR=1.18, 95% CI = 1.04-1.33, Q=1331, p<0.001).
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
Insert figure 4 here
Discussion
This is the first meta-analysis to our knowledge to investigate if there is a disparity in smoking cessation advice rates in people with mental illness compared to the general population. Our results demonstrate that overall people with mental illness (including SMI) are broadly offered comparable rates of smoking cessation advice to members of the general population (RR=1.02, 95% CI 0.94- level of cessation advice could remain a concern given the greatly increased smoking rates among people with mental illness and the physical illnesses and premature mortality directly attributable to smoking in people with mental illness. Whilst progress has been made, equivocal interventions may not enough for this highly at risk population that has competing problems such as low socioeconomic status, poor social support, and comorbid substance abuse. More intensive, multi-faceted interventions may need to be developed to reach this vulnerable population. This effect appeared to hold true even in those with schizophrenia alone and in those with bipolar illness alone (RR=1.09, 95%CI 0.68-1.77 and RR=1.14, 95% CI 0.85-1.54 respectively). Only in cases of non-severe mental illness were rates higher and then only modest so by about 16%.
Smoking cessation interventions are broadly as effective in people with mental illness, including those with SMI, as with members of the general population 21 . Therefore a failure to offer significantly greater levels of advice cannot be ascribed to therapeutic apathy. That said surveys of mental health professionals suggest only a minority feel that patients' smoking was their responsibility or would make time to treat smoking 48 .
Yet both the American and European
Psychiatric Associations recommend it as a frontline clinical intervention 9, 49 . The findings from . Since people with mental illness experience a wide range of barriers to stopping smoking 9 it is important that members of the MDT take the lead and give advice . Another important consideration of the results from this review is that several of these studies (e.g. 41, 42, 45, 46 ) specifically recruited people with pre-existing physical comorbidities (diabetes or CHD). Whilst smoking cessation advice is a relatively new concept among people with mental illness, it is established among people with diabetes and CHD and this may have influenced the advice rates recorded.
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Therefore, the smoking cessation advice rates observed in these studies is likely to be due to a greater sensitivity among providers to the poorer physical health of this group. It remains however unclear if smoking cessation advice rates and support are comparable in people newly diagnosed with a mental illness. Future research should consider people experiencing their first-episode of psychosis, since a previous meta-analysis 53 has already demonstrated significantly higher rates of smoking compared with the general population early in the disease.
Clinical implications
The receipt of higher rates of smoking cessation advice in non SMI is initially encouraging, although it is in reality small and clearly not entirely satisfactory. It is concerning that in more severe forms of mental illness rates of received advice are often lower than in milder forms. There is strong evidence from previous studies that patients with schizophrenia and bipolar disorder receive inadequate medical care which may influence health outcomes such as mortality 29 . We suggest failure to offer enhanced smoking cessation advice could be one factor maintaining high mortality in SMI. Provision of lifestyle advice within the psychiatric consultation is now promoted as a matter of routine 5 , but our findings do indicate that advice on smoking may still not be offered systematically to all with mental illness that smoke. Because smoking cessation rates following interventions and advice are comparably effective with those observed in the general population, we believe that smoking cessation advice and associated therapeutic interventions and drug treatment are promoted by mental health MDT's. The current review findings clearly demonstrate that it is important to give psychiatrists, but also primary care physicians training in smoking cessation advice in people with mental illness. The treatment of tobacco dependence should for example be incorporated into the catalogue of disorders to be studied during specialist training in psychiatry. However, offering smoking cessation advice should not be isolated to qualified doctors and all members of the MDT and in particular nurses may help in this process.
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The American 49 and European 9 Psychiatric Associations recommend that psychiatrists should routinely assess a patient's smoking status (e.g., current smoker, ex-smoker, never smoked, number of cigarettes per day). A procedure analogous to the so-called '4 A Intervention' may be recommended for short-term interventions: (1) Ask; (2) Advise; (3) Assist; (4) Arrange. Treating psychiatrists should thus: (1) ask about the patient's smoking habits; (2) clearly advise the patient to quit smoking; (3) offer the patient psychological support during smoking cessation and explain pharmacological aids; and (4) arrange follow-up visits to check that the patient is still abstinent.
Other adaptations to this model, including the 5A's are also available and can be considered Clinician advice to discontinue smoking is best given in a non-judgmental, empathic and supportive manner 56 . A 'quit day' should be set or gradual reduction of tobacco consumption could be proposed as an alternative approach 57 , especially as this method was recently found to have a comparable abstinence effect to quitting abruptly 58 . Thus, both methods can be recommended. To increase the quit rate, established programmes (individual therapy, group therapy, telephone coaching) should however be employed wherever available 56 .
Limitations
Whilst this is the first review of its kind, a number of limitations must be considered along with the results which are reflections of limitations in the primary studies. First, we pooled data on several different types of mental illness within the main analysis. However, this is reflective of the range of mental illnesses seen by mental health services. We attempted to increase clinical homogeneity by conducting subgroup analysis for those with and without SMI and further attempted to reduce heterogeneity within these subgroup analyses. Second, it is unsurprising to note that each of the analysis demonstrated statistical heterogeneity. Third, all of the studies included within the meta-
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analysis were from the UK or the US and it remains unclear if the results are generalizable outside these countries. Fourth, most of the studies included older and people with mental illness (over 50 years of age) that had pre-existing physical comorbidities (e.g. diabetes and CHD) and no data is available on people newly diagnosed with mental illness. This means it is likely that our results may be an overestimation of smoking cessation rates and such rates in younger populations are unclear and warrant future research. Particular attention should be given to those presenting with their first episode psychosis. Fifth, details regarding the type and nature of smoking cessation advice were limited in the original manuscripts and it is unclear how heterogeneous these interventions were.
Lastly, a number of the included studies appeared to demonstrate lower levels of mental illness than one would expect. Thus, the samples of some studies may be biased to some extent.
Future Research
Future research should seek to investigate if there are differences in the rates of smoking cessation advice given to people that are newly diagnosed with a mental illness. Of great importance is prospective research to investigate the most effective type of smoking cessation advice on quitting rates in patients with mental illness and their health outcomes. Such research should inform clinical practice. In particular, research is warranted to investigate smoking cessation advice rates and outcomes in younger people with mental illness.
Conclusion
People with severe mental illness are not offered any higher rates of smoking cessation advice to members of the general population without severe mental illness. People with mild mental illness appear to be offered slightly higher rates of smoking cessation. This is despite the 2-4 higher rates of smoking in people with mental illness and the drastically increased morbidity and mortality attributed to tobacco use. Clinicians should be given training about smoking cessation advice in this Bias assessment plot A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT A C C E P T E D M A N U S C R I P T 
ACCEPTED MANUSCRIPT
